Assessment of treatment modalities and outcome of antiVEGF therapy in a clinical setting

What is it about?

Real life data usually fall behind expectations rised by prospective studies. This is mainly attributed to a lower number of injections in a "real-life" setting. Investigating our data we asked which factors would contribute to the low number of injections in real-life. Is it the more advances stages we treat? Is it an inability to treat a high number of patients adequately? Or can it be attributed to a lack of patients' adherence to therapy? A subgroup Analysis Shows the influence of those factors. Interestingly, adherence to therapy seems to have the highest impact on Long term outcome.

Featured Image

Why is it important?

This is a relative large retrospective study covering ~1000 cases, and a follow up of up to 5 years